Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

Inclusion Criteria: * Patients of age ≥18 years who undergo isolated CABG for coronary artery disease * POAF that persists for \>60 minutes or is recurrent (more than one episode) within 7 days after the index CABG surgery Exclusion Criteria: * Clinical history of either permanent, persistent or paroxysmal atrial fibrillation * Any pre-existing clinical indication for long-term OAC * Any absolute contraindication to OAC * Planned use of post-operative dual antiplatelet therapy (DAPT) a. This includes, but is not limited to, patients with recent PCI with drug-eluting or bare-metal stent. * Cardiogenic shock * Major perioperative complication\* occurring between CABG and randomization a. including, but not limited to, stroke, TIA, MI, major bleeding (BARC type 4 bleeding), severe sepsis, renal failure requiring dialysis, or need for reoperation due to bleeding (e.g. pericardial tamponade). * Concomitant left atrial appendage closure during CABG * Concomitant valve surgery during CABG or prior valve surgery (including aortic, mitral, tricuspid or pulmonary) * Concomitant mitral valve annuloplasty during CABG * Concomitant carotid artery endarterectomy during CABG * Concomitant aortic root replacement during CABG * Concomitant surgery for AF during CABG * Liver cirrhosis or Child-Pugh Class C chronic liver disease * Pharmacologic therapy with an investigational drug or device within 30-days prior to randomization or plan to enroll patient in an investigational drug or device trial during participation in this trial * Pregnancy at the time of randomization * Unable or unwilling to provide inform consent * Unable or unwilling to comply with the study treatment and follow-up * Existence of underlying disease that limits life expectancy to less than one year